Vertex Pharmaceuticals INC VERTEX.../  US92532F1003  /

London International
2024-05-21  4:32:10 PM Chg. - Volume Bid6:00:04 AM Ask6:00:04 AM Market Capitalization Dividend Y. P/E Ratio
443.20USD - 1,241
Turnover: 45,649.17
-Bid Size: - -Ask Size: - 124.71 bill.USD - 34.40

Fundamentals

  FY 2023 Growth (1Y)
Per Share  
Earnings per Share: 14.05 USD 8.33%
EPS Diluted: 13.89 USD 8.35%
Revenues per Share: 38.21 USD 9.99%
Book Value per Share: 68.06 USD 25.77%
Cash Flow per Share: 13.69 USD -14.75%
Dividend per Share: - USD -
Total in mill.  
Revenues: 9,869.20 USD 10.51%
Net Income: 3,619.60 USD 8.96%
Operating Cash Flow: 3,537.30 USD -
Cash and Cash Equivalents: 10,369.10 USD -

Valuation Ratios

  Current Latest FY*
P/E Ratio: 34.40 28.96
P/S Ratio: 12.65 10.65
P/BV ratio: 7.10 5.98
P/CF Ratio: 35.29 29.71
PEG: 4.13 3.48
Earnings Yield: 2.91% 3.45%
Dividend Yield: - -
Market Capitalization  
Market Capitalization: 124.71 bill. USD 105.1 bill. USD
Free Float Market Cap.: - USD - USD
Market Cap. / Employee: - USD - USD
Shares Outstanding: 258.05 mill.  
 

Profitability

Gross Profit Margin: 87.21%
EBIT Margin: 38.83%
Net Profit Margin: 36.68%
Return on Equity: 20.59%
Return on Assets: 15.92%

Financial Strength

Liquidity I / Cash Ratio: 292.30%
Liquidity II / Quick Ratio: 336.37%
Liquidity III / Current Ratio: 398.72%
Debt / Equity Ratio: 29.29%
Dynam. Debt / Equity Ratio: 145.59%

Efficiency

Employees: -
Personal Expenses / Employee: - USD
Revenues / Employee: - USD
Net Income / Employee: - USD
Total Assets / Employee: - USD
 
* Fiscal Year End: 2023-12-31
Accounting Standard: US GAAP
Currency: USD